- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07947498
Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial Infarction (MI-Holter)
Evaluation of the Prognostic Value of Long-term(2 Weeks) Electrocardiogram Analysis After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
This single-center, single-group study will evaluate the prognostic value of long-term electrocardiographic monitoring in adults with acute myocardial infarction who undergo primary percutaneous coronary intervention. After written informed consent, eligible participants will have a MEMO Patch2 long-term Holter monitor applied on the day of, or the day after, the procedure and will wear it for 2 weeks. The study will classify high-risk arrhythmias detected during monitoring and compare long-term clinical outcomes according to arrhythmia classification.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Patients presenting with acute myocardial infarction and undergoing primary percutaneous coronary intervention will be screened at Chungnam National University Hospital. Eligible adults who understand the study and provide written informed consent will be enrolled.
A MEMO Patch2 long-term Holter monitor will be attached on the day of, or the day after, the procedure. Participants will wear the device for 2 weeks and have it removed at an outpatient visit, after which the electrocardiographic recordings will be analyzed. Recorded arrhythmias include ventricular tachycardia, ventricular fibrillation, nonsustained ventricular tachycardia, atrial fibrillation, atrial flutter, high-degree atrioventricular block, and ventricular premature complexes.
The primary objective is to classify high-risk arrhythmias detected by 2-week monitoring. The secondary objective is to compare long-term prognosis according to arrhythmia classification, including all-cause death, cardiac death, noncardiac death, rehospitalization for heart failure, recurrent myocardial infarction, and stroke. Baseline diseases, laboratory results, social history, coronary intervention findings, prescribed medications, height, weight, and body mass index will also be collected. Statistical analyses described in the Protocol include descriptive statistics, t-tests, chi-square tests, Pearson correlation, multiple regression, multiple Cox regression, and Kaplan-Meier survival analysis, with a two-sided significance level of p<0.05.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: JunHyung Kim
- Número de telefone: +82-042-280-8237
- E-mail: william@cnu.ac.kr
Locais de estudo
-
-
-
Daejeon, Coréia do Sul, 35015
- Recrutamento
- Chungnam National University Hospital
-
Contato:
- JunHyung Kim
- Número de telefone: +82-042-280-8237
- E-mail: william@cnu.ac.kr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Adult aged 20 years or older.
- Diagnosed with STEMI and underwent primary percutaneous coronary intervention; or diagnosed with NSTEMI, underwent primary percutaneous coronary intervention, and meets at least one of the following conditions: (a) left ventricular ejection fraction ≤45% on echocardiography; (b) ventricular tachycardia, ventricular fibrillation, atrial fibrillation, or high-degree atrioventricular block during or after percutaneous coronary intervention (ventricular tachycardia is defined as ≥3 consecutive ventricular premature complexes); or (c) post-procedural TIMI flow grade 0-2 during percutaneous coronary intervention.
- Has received and understood an explanation of the study and signed the informed consent form.
Exclusion Criteria:
- Refuses to participate in the study.
- Is transferred to another hospital immediately after the procedure and cannot be followed.
- Is unable to express an intention to participate in the study, such as due to unconsciousness.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: MEMO Patch2 Long-Term Holter Monitoring
Participants with acute myocardial infarction who undergo primary percutaneous coronary intervention will have a MEMO Patch2 long-term Holter monitor attached on the day of, or the day after, the procedure. The device will be worn continuously for 2 weeks and removed at an outpatient visit. Recorded arrhythmias will be analyzed, and long-term prognosis will be compared according to arrhythmia classification. |
MEMO Patch2 is a detachable long-term Holter monitoring device. It will be applied on the day of, or the day after, primary percutaneous coronary intervention and worn for 2 weeks to record arrhythmias that may be missed by in-hospital monitoring. It will be removed at an outpatient visit, and the recordings will then be analyzed.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Classification of High-Risk Arrhythmias
Prazo: At the outpatient visit after completion of the 2-week MEMO Patch2 monitoring period
|
High-risk arrhythmias detected by MEMO Patch2 will be classified. Arrhythmias assessed include ventricular tachycardia, ventricular fibrillation, nonsustained ventricular tachycardia, atrial fibrillation, atrial flutter, high-degree atrioventricular block, and ventricular premature complexes. |
At the outpatient visit after completion of the 2-week MEMO Patch2 monitoring period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Long-Term Prognosis According to Arrhythmia Classification
Prazo: Through study completion (anticipated 2026-12-31)
|
Long-term prognosis will be compared according to arrhythmia classification. Outcomes include all-cause death, cardiac death, noncardiac death, rehospitalization for heart failure, recurrent myocardial infarction, and stroke. |
Through study completion (anticipated 2026-12-31)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Vasculares
- Doenças cardiovasculares
- Processos Patológicos
- Doenças cardíacas
- Infarte
- Necrose
- Isquemia do miocárdio
- Infarto do miocárdio
- Isquemia
- Condições Patológicas, Sinais e Sintomas
- Infarto do Miocárdio com Elevação do ST
- Infarto do Miocárdio Sem Elevação do ST
- Fibrilação atrial
- Arritmias Cardíacas
Outros números de identificação do estudo
- MI-Holter
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Individual participant data collected in this study are not planned to be shared with external researchers. Any future sharing would require separate sponsor approval and compliance with applicable privacy, ethical, and institutional requirements.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .